← Back to screener

Nautilus Biotechnology, Inc. NAUT

Rank #1750 · Nasdaq · $0.3B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
43.0
P/E
-4.9
P/B
1.31
ROE
-26.7%
Op. Margin
–%
Debt Ratio
13%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -4.9x, P/B 1.31x. Ranks in the top 56% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -26.7%. Ranks in the top 83% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 13%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–––$0.0B––
2021––$-0.0B$-0.0B–-44
2022––$-0.1B$-0.0B–-117
2023––$-0.1B$0.4B–10
2024––$-0.1B$0.3B–13
2025––$-0.1B$0.3B–13

← See the full screener